- Home
- SSP vs GNLX Comparison
SSP vs GNLX Comparison
Compare SSP & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSP
- GNLX
- Stock Information
- Founded
- SSP 1878
- GNLX 2001
- Country
- SSP United States
- GNLX United States
- Employees
- SSP N/A
- GNLX N/A
- Industry
- SSP Broadcasting
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- SSP Industrials
- GNLX Health Care
- Exchange
- SSP Nasdaq
- GNLX Nasdaq
- Market Cap
- SSP 187.3M
- GNLX 184.4M
- IPO Year
- SSP 1988
- GNLX 2023
- Fundamental
- Price
- SSP $2.59
- GNLX $2.85
- Analyst Decision
- SSP Buy
- GNLX Strong Buy
- Analyst Count
- SSP 2
- GNLX 4
- Target Price
- SSP $6.25
- GNLX $17.75
- AVG Volume (30 Days)
- SSP 772.5K
- GNLX 148.2K
- Earning Date
- SSP 05-08-2025
- GNLX 05-06-2025
- Dividend Yield
- SSP N/A
- GNLX N/A
- EPS Growth
- SSP N/A
- GNLX N/A
- EPS
- SSP 1.01
- GNLX N/A
- Revenue
- SSP $2,509,772,000.00
- GNLX N/A
- Revenue This Year
- SSP N/A
- GNLX N/A
- Revenue Next Year
- SSP $9.18
- GNLX N/A
- P/E Ratio
- SSP $2.37
- GNLX N/A
- Revenue Growth
- SSP 9.46
- GNLX N/A
- 52 Week Low
- SSP $1.36
- GNLX $1.60
- 52 Week High
- SSP $4.65
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- SSP 58.30
- GNLX 52.02
- Support Level
- SSP $2.25
- GNLX $2.26
- Resistance Level
- SSP $2.48
- GNLX $3.08
- Average True Range (ATR)
- SSP 0.19
- GNLX 0.30
- MACD
- SSP 0.05
- GNLX 0.02
- Stochastic Oscillator
- SSP 87.74
- GNLX 66.18
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.